A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
The patient or his/her guardian voluntarily signed the informed consent;
Age >18 years and ≤70 years, male or female;
Recurrent/metastatic/persistent cervical cancer with prior failure (disease progression or intolerable toxicity) of at least 1 but no more than 3 systemic therapies;
Systemic therapy is defined as any chemotherapy or multi-drug combination chemotherapy regimen recommended by guidelines used for cervical cancer;
Presence of bone metastases only.
Active central nervous system (CNS) metastases (except for stable brain metastases not requiring medication or steroid dependence for ≥3 months).
Use of Chinese herbal medicine or botanical drugs with antitumor indications within 1 week before preconditioning.
Systemic corticosteroid therapy (≥10 mg/day prednisone or equivalent) or other immunosuppressive drugs within 2 weeks before preconditioning (excluding inhaled, topical, or physiological replacement therapy).
Anhui Provincial Hospital
Lead sponsor
Leman Biotech Co., Ltd.
Collaborator